(thirdQuint)Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine.

 This multicenter study is open with respect to the treatment allocation, but double-blind with respect to the Hib-MenC-TT lots (3 lots).

 The study will be conducted in two stages.

 Primary vaccination phase: 3 doses Hib-MenC-TT with Infanrix cent -IPV or for the control group a licensed Men-C vaccine with Pediacel cent at 2, 3, 4 months of age; Booster/persistence phase: 1 dose Hib-MenC with Priorix cent .

 4 blood samples of 3.

5ml (5ml for the UK subset) are collected (Study Months 0 & 3, prior to & 42 days after the booster).

.

 Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine@highlight

The purpose of this study is to demonstrate the non-inferiority of the candidate Hib-MenC conjugate vaccine co-administered with Infanrix cent -IPV versus a licensed meningococcal serogroup C vaccine co-administered with Pediacel cent when given according to a 2, 3, 4 month schedule and the immunogenicity of the Hib-MenC vaccine when given as a booster dose at 12-15 months of age.

